ValuEngine Lowers Agilent Technologies (A) to Hold

ValuEngine downgraded shares of Agilent Technologies (NYSE:A) from a buy rating to a hold rating in a research report report published on Tuesday.

A has been the subject of a number of other reports. Goldman Sachs Group raised shares of Agilent Technologies from a neutral rating to a buy rating in a research report on Monday, April 9th. Zacks Investment Research raised shares of Agilent Technologies from a hold rating to a buy rating and set a $76.00 price objective for the company in a research report on Tuesday, March 27th. Morgan Stanley reduced their price objective on shares of Agilent Technologies from $95.00 to $91.00 and set an overweight rating for the company in a research report on Wednesday, April 11th. Cowen raised shares of Agilent Technologies from a market perform rating to an outperform rating in a research report on Tuesday, May 15th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Agilent Technologies from $75.00 to $80.00 and gave the stock an overweight rating in a research report on Thursday, February 15th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $72.75.

Agilent Technologies opened at $61.92 on Tuesday, MarketBeat Ratings reports. Agilent Technologies has a 1-year low of $57.92 and a 1-year high of $75.00. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.32 and a quick ratio of 2.88. The firm has a market capitalization of $19.95 billion, a P/E ratio of 26.24, a PEG ratio of 2.16 and a beta of 1.32.

Agilent Technologies (NYSE:A) last released its earnings results on Monday, May 14th. The medical research company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.01. Agilent Technologies had a net margin of 5.02% and a return on equity of 18.01%. The business had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same period last year, the business earned $0.58 earnings per share. The firm’s revenue was up 9.4% on a year-over-year basis. sell-side analysts anticipate that Agilent Technologies will post 2.67 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 25th. Stockholders of record on Tuesday, July 3rd will be issued a dividend of $0.149 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend is Monday, July 2nd. Agilent Technologies’s dividend payout ratio is currently 25.42%.

In related news, insider Patrick Kaltenbach sold 4,000 shares of the business’s stock in a transaction dated Thursday, March 29th. The stock was sold at an average price of $67.28, for a total value of $269,120.00. Following the completion of the transaction, the insider now owns 72,547 shares of the company’s stock, valued at $4,880,962.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Rodney Gonsalves sold 6,825 shares of the business’s stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $71.23, for a total value of $486,144.75. The disclosure for this sale can be found here. Insiders have sold 22,700 shares of company stock valued at $1,586,452 in the last three months.

Hedge funds have recently bought and sold shares of the stock. Leucadia National Corp acquired a new position in Agilent Technologies in the fourth quarter valued at about $1,647,000. BlackRock Inc. raised its stake in Agilent Technologies by 8.1% during the fourth quarter. BlackRock Inc. now owns 25,665,358 shares of the medical research company’s stock worth $1,718,808,000 after acquiring an additional 1,912,186 shares in the last quarter. Rhumbline Advisers raised its stake in Agilent Technologies by 1.7% during the fourth quarter. Rhumbline Advisers now owns 558,724 shares of the medical research company’s stock worth $37,418,000 after acquiring an additional 9,438 shares in the last quarter. Sciencast Management LP raised its stake in Agilent Technologies by 30.9% during the fourth quarter. Sciencast Management LP now owns 18,148 shares of the medical research company’s stock worth $1,326,000 after acquiring an additional 4,279 shares in the last quarter. Finally, MetLife Investment Advisors LLC acquired a new position in Agilent Technologies during the fourth quarter worth about $6,669,000.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply